Atorvia is pioneering first-in-class peptide therapeutics to treat organ failure, starting with acute kidney injury (AKI). Affecting one in four cardiac surgery patients, AKI currently has no effective therapy and often leads to severe complications. Our single-dose IV treatment protects the kidneys, shortens ICU stays, and reduces hospital costs. Backed by a team with deep experience in biomedical discovery and commercialization, Atorvia is dedicated to creating a future where no one suffers fr…